诺华公司上调了全年利润展望，因为新药增长日益抵消了昔日畅销药Entresto（沙库巴曲缬沙坦钠片）面临仿制药竞争带来的冲击。
AG raised its profit outlook for the year as growth from newer medicines increasingly offset the hit from generic competition to former blockbuster Entresto.
这家瑞士药企周二表示，按固定汇率计算，每股收益（不含某些项目）可能基本持平或以低个位数百分比增长。此前公司曾预期会出现下降。
Earnings per share excluding some items may show little change or grow by a low single-digit percentage at constant currencies, the Swiss drugmaker said Tuesday. The company had previously anticipated a decline.
随着廉价仿制药蚕食部分前畅销药的销售，诺华需要新药来驱动增长。在遭遇三次临床试验挫折后，这种压力正在加大，这提高了剩余疗法（如一种治疗多发性硬化症的实验性药丸）的成败关键性。
Novartis needs new medicines to power growth as cheaper copies eat into sales of some of its former best—sellers. The pressure is ratcheting up after three clinical trial setbacks, raising the stakes for remaining treatments like an experimental pill for multiple sclerosis.
上个月，诺华股价单日暴跌11%，创下六年多来最大跌幅，原因是一种治疗罕见肌肉萎缩症的疗法在晚期研究中失败；此后股价已基本收复失地。公司在最近几个月回购了价值47亿美元的股份。
Novartis shares have largely recovered after plunging 11% in a day last month, the worst drop in more than six years, when a treatment for a rare muscle-wasting disease failed a late-stage study. The company bought back $4.7 billion worth of shares in recent months.
这种名为del-desiran的药物是诺华120亿美元收购Avidity Biosciences的核心资产，首席执行官纳拉西姆汉曾将其吹捧为潜在的大爆款药物。这一失败打击了旨在驱动2030年后增长的药物之一，并引发了对纳拉西姆汉交易决策的质疑。
The medicine, del-desiran, was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and touted by Chief Executive Officer Vas Narasimhan as a potential blockbuster. The failure dealt a blow to one of the medicines intended to drive growth beyond 2030 and raised questions about Narasimhan’s dealmaking.
由于计提19亿美元减值费用以减记del-desiran的价值，公司上季度营业利润大幅下滑。不过核心利润却有所上升，超出分析师预期。
The company’s operating profit plunged last quarter after it took a $1.9 billion impairment charge to write down the value of del-desiran. Core profit rose, however, exceeding analysts’ estimates.
今年以来该股累计上涨约16%，表现落后于瑞士竞争对手罗氏控股，后者也计划推出一种新的多发性硬化症疗法。
The stock has climbed about 16% so far this year, underperforming Swiss rival Roche Holding AG, which also plans to introduce a new multiple sclerosis therapy.
诺华上周表示，在研究中，名为瑞米布替尼的疗法使自身免疫性疾病患者的年复发率比赛诺菲的老牌药物 Aubagio（特立氟胺）降低了约三分之一。这一结果低于预期，促使一些分析师下调了该药物的销售预测。另一些分析师则更为乐观，指出与罗氏的非奈布替尼相比，该药在肝脏安全性方面具有更好的副作用特征。这两款药物将在一个可能达到数十亿美元规模的市场上展开竞争。
Novartis last week said the treatment called remibrutinib cut annual relapse rates for patients with the autoimmune condition by about a third compared with Sanofi’s older drug Aubagio in studies. That was less than expected, prompting some analysts to trim their sales estimates for the drug. Others were more upbeat, pointing to a better side-effects profile than Roche’s fenebrutinib for liver safety. The two medicines will compete in what could be a multibillion-dollar market.